Suppr超能文献

尼美舒利是一种选择性COX - 2抑制剂,属于非典型非甾体抗炎药。

Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug.

作者信息

Suleyman H, Cadirci E, Albayrak A, Halici Z

机构信息

Ataturk University, Faculty of Medicine, Department of Pharmacology, 25240 Erzurum, Turkey.

出版信息

Curr Med Chem. 2008;15(3):278-83. doi: 10.2174/092986708783497247.

Abstract

In this review it is shown that nimesulide, a selective cyclooxigenase-2 (COX-2) inhibitor, is different from other selective COX-2 inhibitors and classical non-steroidal anti-inflammatory drugs (NSAIDs). The anti-inflammatory effect mechanism of nimesulide (inhibition of inflammatory mediators) is similar to other classic NSAIDs, but the protective effect of nimesulide on classic NSAID-induced ulcers elucidates the difference between nimesulide and these other drugs. It is known that the selective COX-2 inhibitor nimesulide prevents NSAID-induced ulcers, while celecoxib and rofecoxib, which are more selective to COX-2, failed to prevent these ulcers. Nimesulide produces gastro-protective effects via a completely different mechanism. In addition, while selective COX-2 inhibitors increase the risk for cardiovascular diseases, nimesulide does not exert significant cardiotoxicity. This data suggests that gastrointestinal side effects of classic NSAIDs cannot be related to the COX-1 inhibition alone and also suggest that nimesulide is an atypical NSAID, which is different from both non-selective and selective COX-2 inhibitors.

摘要

本综述表明,尼美舒利作为一种选择性环氧化酶-2(COX-2)抑制剂,不同于其他选择性COX-2抑制剂和传统非甾体抗炎药(NSAIDs)。尼美舒利的抗炎作用机制(抑制炎症介质)与其他传统NSAIDs相似,但尼美舒利对传统NSAIDs诱导的溃疡的保护作用阐明了其与其他药物的差异。已知选择性COX-2抑制剂尼美舒利可预防NSAIDs诱导的溃疡,而对COX-2选择性更高的塞来昔布和罗非昔布则未能预防这些溃疡。尼美舒利通过完全不同的机制产生胃保护作用。此外,虽然选择性COX-2抑制剂会增加心血管疾病风险,但尼美舒利不会产生显著的心脏毒性。这些数据表明,传统NSAIDs的胃肠道副作用不能仅归因于COX-1抑制,也表明尼美舒利是一种非典型NSAID,不同于非选择性和选择性COX-Ⅱ抑制剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验